United Health Products, Inc.

      • Market Cap $17.32M
      • Debt $357.50K
      • Cash $43.78K
      • EV $17.63M
      • FCF -

      Earnings

      loading chart...

      Sales & Net Margins

      loading chart...
      Earnings-$1.66M
      EBIT-$1.67M
      ROA-1K%
      Equity-$2.11M
      Growth Stability1
      PE-10.43
      PB-8.2
      Price/Cash0
      Debt/Equity-0.17
      Sales CAGR-14%
      Equity CAGR-1%
      Earnings Growth YoY-37%
      Earnings Growth QoQ-30%
      Sales CAGR 5Y16%
      Earnings CAGR 3Y34%
      Sales CAGR 3Y34%
      Market Cap$17.32M
      Revenue$0.00
      Assets$150.63K
      Total Debt$357.50K
      Cash$43.78K
      Shares Outstanding247.37M
      EV17.63M
      Working Capital-2.17M
      Current Ratio0.03
      Shares Growth 3y3%
      Equity Growth QoQ5%
      Equity Growth YoY18%

      Assets & ROA

      loading chart...

      Stockholders Equity & ROE

      loading chart...
      United Health Products Inc is a US-based company. It mainly manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. The company's product HemoStyp is derived from regenerated oxidized cellulose, which is naturally designed to absorb exudate from superficial wounds and helps control bleeding. It markets its product to dental and medical markets as well as, sports, military and veterinary sectors, and others. The company's product line includes trauma gauze, dental gauze, hemostrip, boo boo strips and others.

      SEC Filings

      Direct access to United Health Products, Inc. (UEEC) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

      • 2024
        • 10-Q Sep 30
        • 10-Q Jun 30
        • 10-Q Mar 31
      • 2023
        • 10-K Dec 31
        • 10-Q Sep 30
        • 10-Q Jun 30
        • 10-Q Mar 31
      • 2022
        • 10-K Dec 31
        • 10-Q Sep 30
        • 10-Q Jun 30
        • 10-Q Mar 31

      Sector Comparison

      How does United Health Products, Inc. compare to its competitors?

      Not enough data to generate a comparison chart between United Health Products, Inc. and its competitors. Please check back later.

      Peter Lynch's Chart

      This chart shows the current pricing of United Health Products, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

      loading chart...

      United Health Products, Inc. Discounted Cash Flow

      Fully customizable DCF calculator online for United Health Products, Inc..

      0
      012345678910TV
      fcf$0$0$0$0$0$0$0$0$0$0$0$0
      DCF$0$0$0$0$0$0$0$0$0$0$0
      Value$0

      Competitiveness and MOAT

      High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

      Years12/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
      Net Margins-5K%-221%-145%-13K%-134K%-2M%-52M%-5K%--
      ROA--263%-88%-2K%-7K%-7K%-111K%-799%-852%-1K%
      ROE-71%358%2K%730%2K%3K%82%153%-

      Safety and Stability

      Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

      Years12/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
      Debt over FCF------0.32-0.4---
      Debt over Equity-0.14-0.24-1.03-0.02-0.4-0.48-0.29-0.14-0.12-0.17
      Growth Stability---------1

      Growth

      Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

      Years12/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
      Revenue YoY growth-354%167%-93%-89%-87%-91%63K%-100%16%
      Earnings YoY growth--79%75%542%10%138%94%-94%55%-
      Equity YoY growth--6%-65%35%156%5%20%81%-17%-
      FCF YoY growth------19%-42%---